Program

The International Workshop on Clinical Pharmacology of Tuberculosis Drugs collaborates with a committed group of international experts in the field of clinical pharmacology of tuberculosis drugs. By working together with our extensive global network of experts from various backgrounds in the field, we will deliver the most relevant and state-of-the-art program.

 

Tuesday, 10 September 2019

  08:30

Workshop Opening
Rob Aarnoutse, PharmD, PhD
Radboud University Medical Center, The Netherlands

 Session 1: Pharmacokinetics and Pharmacodynamics of New and Repurposed TB Drugs
  08:45 Oxazolidinones for TB: Current Status and Future Prospects
Dr. Lawrence Geiter
  Discussion
  Oral Abstract Presentations
  09:15 Evaluating Hepatotoxicity of Bedaquiline Treatment in Multi-Drug Resistant Tuberculosis Patients
Lénaïg Tanneau
 
  09:30Relationship Between Plasma and Intracellular Concentrations of Bedaquiline and its M2 Metabolite in South African Patients with Drug-Resistant TB
Precious Ngwalero
 
  09:45Co-Administration of Pretomanid with Rifampin or Rifabutin Among Patients with Pulmonary TB: Interim PK Results from “Assessing Pretomanid for Tuberculosis” (APT) Trial
Dr. Elisa Ignatius
 
  10:00Pharmacokinetics and Early Bactericidal Activity of Meropenem (with Amoxicillin/Clavulanate), With and Without Rifampicin, for Drug-Susceptible TB
Dr. Ahmed Aliyu Abulfathi
 
 

 10:15    Discussion

 10:30Coffee Break
  
 Session 2: Pharmacokinetics and Pharmacodynamics of Established TB Drugs
  Oral Abstract Presentations
  11:00Pharmacogenetics and Pharmacokinetics of First-Line Anti-Tuberculosis Drugs in the HIRIF Trial
Dr. Elizabeth Mackay
  11:15Increased Bactericidal Activity but Dose-Limiting Tolerability at 50 mg/kg Rifampicin
Dr. Lindsey Te Brake
 
  11:30Ethionamide Population Pharmacokinetic Model and Monte Carlo Simulation in Patients with Multidrug-Resistant Tuberculosis
Dr. Charles Peloquin
 
  11:45Exposures to First-Line Drugs in African and Indian Children with Drug-Susceptible Tuberculosis using Novel Fixed-Dose-Combination Tablets at WHO Dosing Recommendation in the SHINE Trial
Dr. Chishala Chabala
 
  12:00The OptiRIF Study: Pharmacokinetics of High-Dose Rifampicin in Children
Dr. Elin Svensson
 
  12:15Discussion 
    
  
 12:30Lunch
  
 

13:15

Guided Poster Session
Dr. Charles Peloquin 
 

Mechanistic Modelling of Time-to-Positivity and Colony-Forming Unit in Tuberculosis Patients on High-Dose Rifampicin to Improve Understanding of Biomarker Relation
Ahmad Rami Ayoun Alsoud

Population Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis Patients
Dr. Elin Svensson

Optimal Dose Individualisation of Rifampicin needs to Account for Between-Occasion Variability
Lina Keutzer

Levofloxacin Urine Kinetics and Development of a Colorimetric Assay for Therapeutic Drug Monitoring Among People Living with HIV and TB
Daniel Van Aartsen

Mathematical Modeling using In Vitro Checkerboard Assay Data: Clofazimine as a Potentially Synergistic Anti-TB Drug
Dr. Charles Peloquin

Comparison of a Bayesian Forecasting Algorithm Handling Inter-Occasion Variability and a Linear Regression Approach for Dose Individualization of Rifampicin
Selma El Messaoudi

Protein Binding Determination of Second-Line Anti-Tuberculosis Drugs In Vitro using an Ultrafiltration Technique
Dr. Charles Peloquin

 Session 3: Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Modelling
  14:00Pharmacokinetic-Pharmacodynamic Analysis in TB Drug Development and the Role of the WHO
Dr. Ernesto Jaramillo
  Discussion
  Oral Abstract Presentations
  14:30Can Longitudinal PKPD Biomarkers be used to Forecast Treatment Outcome Instead of M2 Conversion? A Population Pharmacokinetic-Pharmacodynamic Analysis in Drug Sensitive Pulmonary Tuberculosis
Dr. Frank Kloprogge
 
  14:45PK-PD of Isoniazid Given at Different Doses Among Patients with MDR-TB with INH Resistance Mediated by inhA Mutations: Modeling Results from ACTG A5312
Kamunkhwala Gausi
 
  15:00Population Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment Analysis
Dr. Charles Peloquin
 
  15:15Levofloxacin Target Attainment Analysis in MDR-TB Patients: Time is Ripe for Proactive TDM
Dr. Mathieu Bolhuis
 
  15:30    Discussion
 15:45Coffee Break
  
 Session 4:  TB Drug Development and Optimization: Approaches and Tools
  16:15

Combined use of Biomarker Data and Drug Exposures to Predict TB Treatment Response
Dr. Elin Svensson

Discussion

  16:45An Assay to Measure Drug Tolerance of M. Tuberculosis in the Caseous Center of Pulmonary Lesions
Jansy Sarathy
 
  17:00A PBPK Modelling Approach to Simulate the Rifampicin-Moxifloxacin Drug-Drug Interaction in TB Patients
Carlijn Litjens
 
  17:15Stratified Dosage Regimens from Early Bactericidal Activity Studies: An Application to Pretomanid
Dr. Michael Lyons
 
  17:30Drug Effect of Clofazimine on Persistent Mycobacteria Explain an Unexpected Increase of Bacterial Load in Patients
Alan Faraj
 
  17:45Discussion 
    
  18:00Closure and Adjournment
  
  Reception
  
 19:30Networking Dinner